GDNF and Parkinson disease: Presently, AAV2-GDNF (adeno-associated virus serotype 2 borne glial cell line-derived neurotrophic factor) is in a non-randomized open-label safety trial developing for PD treatment by Brain Neurotherapy Bio, Inc. (Table 2).